EUVIMEDEUVIMED entdecken
Crossref

Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2

Yonghui Zhang, Yihan Huang, Baowen Dang, Shiting Hu, Chenrui Zhao, Yuejin Wang, Yujuan Yuan, Rui Liu iD

Journal of Pharmacy and Pharmacology · 2023

DOI: 10.1093/jpp/rgad056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Yonghui Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China. Hauptthemen laut MEDLINE: Mast Cells, Chronic Urticaria. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The activation of mast cell (MC) plays an important part in the pathogenesis of chronic urticaria (CU), and the expression of MRGPRX2 (Mas-related G-protein coupled receptor X2) and the circulating levels of SP (substance P) in skin MC of CU patients increased. Fisetin is a natural flavonoid with anti-inflammatory and antiallergic pharmacological effects. This study aimed to investigate the inhibitory effect of fisetin on CU via MRGPRX2 and its possible molecular mechanisms.

Methods

OVA/SP co-stimulated and SP-stimulated CU like murine models were used to evaluate the effect of fisetin on CU. MRGPRX2/HEK293 cells and LAD2 cells were used to perform the antagonism effect of fisetin on MC via MRGPRX2. Key findings The results indicated that fisetin prevented urticaria-like symptoms in murine CU models, and inhibited MCs activation by suppressing calcium mobilization and degranulation of cytokines and chemokines via binding to MRGPRX2. The bioinformatics analysis showed that fisetin might have an interaction relationship with Akt in CU. The western blotting experiments showed that fisetin downregulated the phosphorylation levels of Akt, P38, NF-κB, and PLCγ in C48/80 activated LAD2 cells.

Conclusions

Fisetin alleviates CU progression by inhibiting mast cell activation via MRGPRX2, which may be a novel therapeutic candidate for CU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mast CellsChronic UrticariaCell DegranulationHumansReceptors, NeuropeptideReceptors, G-Protein-CoupledMiceAnimalsHEK293 CellsNerve Tissue ProteinsProto-Oncogene Proteins c-aktFlavonolsCongenital Disorders of Glycosylation

Stichwörter der Autor:innen

MRGPRX2chronic urticariafisetinmast cellssubstance P

Substanzen

Receptors, NeuropeptideReceptors, G-Protein-CoupledNerve Tissue ProteinsProto-Oncogene Proteins c-aktfisetinFlavonolsMRGPRX2 protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.

ORCID-Profile: Rui Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Huang, Y., Dang, B., Hu, S., Zhao, C., Wang, Y., Yuan, Y., & Liu, R. (2023). Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad056

Vancouver

Zhang Y, Huang Y, Dang B, Hu S, Zhao C, Wang Y, et al. Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad056

BibTeX
@article{Zhang2023,
  author = {Zhang, Yonghui and Huang, Yihan and Dang, Baowen and Hu, Shiting and Zhao, Chenrui and Wang, Yuejin and Yuan, Yujuan and Liu, Rui},
  title = {Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2023},
  doi = {10.1093/jpp/rgad056}
}
Kostenlos starten →